drugset
drugset / Trial / NCT01857544

Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy

NCT01857544 ↗

Phase 4 Unknown 10 enrolled Tennessee Retina Regeneron Pharmaceuticals · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is determine the number of patients with complete resolution of macular edema secondary to central retinal vein occlusion following 6 monthly injections of Aflibercept.

Timeline

Start
2013-06
Primary completion
2016-01
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Aflibercept Protein / enzyme biologic 0.05 ml Intravitreal
Subject Aflibercept Protein / enzyme biologic 2 mg Intravitreal

Indications

retinal vein occlusion